Preparation, evaluation and optimization of solid lipid nanoparticles composed of pantoprazole
Abstract
Nanoparticles are a promising medication delivery method that can deliver drugs in a controlled and targeted manner. They're made to release the medicine in close proximity to the target tissue. Solid lipid nanoparticles (SLNs) are a new type of submicron-sized lipid emulsion in which solid lipid replaces liquid lipid (oil). The goal of this study was to create solid lipid nanoparticles (SLN) containing pantoprazole (a proton pump inhibitor) and improve the drug's entrapment efficiency in SLN. This was accomplished by integrating the medication into solvent-injection-prepared solid lipid nanoparticles (SLN). During formulation development, the component concentrations were optimized, and then the particles were characterized in terms of particle size, zeta potential, drug loading, percent drug entrapment, stability studies, and drug release behavior. There was no interaction between the medication and the excipients in FT-IR experiments. The improved formulation's percent EE, particle size, and drug content were found to be 91.88±1.38, 7.16±0.26µm and 97.20±1.46 respectively. F6 was shown to be the most promising formulation among all created formulations in this investigation. For 30 days, stability tests were conducted (F6) at refrigerated temperature (4.0±0.2°C), room temperature (25-28±2°C), and 45±1°C. The current project also aims to improve the formulation's pharmacological acceptability.
Keywords: Solid lipid nanoparticles, Pantoprazole, Solvent-injection method, Entrapment efficiency
Keywords:
Solid lipid nanoparticles, Pantoprazole, Solvent-injection method, Entrapment efficiencyDOI
https://doi.org/10.22270/jddt.v12i1.5154References
Manjunath K, Venkateswarlu VJ. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release, 2005; 107:215-228. https://doi.org/10.1016/j.jconrel.2005.06.006
Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, Ricci M. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm. 2008; 357(1-2):295-304. https://doi.org/10.1016/j.ijpharm.2008.01.045
Mei Z, Li X, Wu Q, Hu S, Yang X. The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle. Pharmacol Res. 2005 Apr; 51(4):345-51. https://doi.org/10.1016/j.phrs.2004.10.007
Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb). 2005; 85(5-6):415-20. https://doi.org/10.1016/j.tube.2005.08.009
Tabatt K, Sameti M, Olbrich C, Müller RH, Lehr CM. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur J Pharm Biopharm. 2004; 57(2):155-62. https://doi.org/10.1016/j.ejpb.2003.10.015
Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008; 60(6):702-16. https://doi.org/10.1016/j.addr.2007.09.007
Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev. 2001; 50(1-2):81-106. https://doi.org/10.1016/S0169-409X(01)00149-1
Hussain N, Jaitley V, Florence AT. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev. 2001; 50(1-2):107-42. https://doi.org/10.1016/S0169-409X(01)00152-1
Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm. 1999; 187(2):143-52. https://doi.org/10.1016/S0378-5173(99)00187-8
Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001; 47(2-3):165-96. https://doi.org/10.1016/S0169-409X(01)00105-3
Westesen K, Bunjas H, Koch MHJ. Physicochemical characterization of lipid 939 nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 1997; 48:223-236. https://doi.org/10.1016/S0168-3659(97)00046-1
Almeida AJ, Runge S, Muller R H. Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int J Pharm, 1997; 149:255-265. https://doi.org/10.1016/S0378-5173(97)04885-0
Rawat M, Singh D, Saraf S, Saraf S. Lipid carriers: a versatile delivery vehicle for proteins and peptides. Yakugaku Zasshi. 2008;128(2):269-80 https://doi.org/10.1248/yakushi.128.269
Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release. 1999; 59(3):299-307. https://doi.org/10.1016/S0168-3659(99)00007-3
Smith A, Hunneyball IM. Evaluation of polylactid as a biodegradable drug delivery system for parenteral administration. Int J Pharm. 1986; 30:215-230. https://doi.org/10.1016/0378-5173(86)90081-5
Muller RH, MaaBen S, Weyhers H, Specht F, Lucks JS. Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN) Int. J. Pharm. 1996; 138:85-94. https://doi.org/10.1016/0378-5173(96)04539-5
Westesen K, Bunjes H. Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix? Int. J. Pharm. 1995; 115:129-131. https://doi.org/10.1016/0378-5173(94)00347-8
Couvreur P, Dubernet C, Puisieux F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur J Pharm Biopharm 1995; 41:2-13.
Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 2007 10; 59(6):478-90. https://doi.org/10.1016/j.addr.2007.04.007
Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol. 2004; 56(12):1527-35. https://doi.org/10.1211/0022357044959
Lim SJ, Lee MK, Kim CK. Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders. J Control Release. 2004 5; 100(1):53-61. https://doi.org/10.1016/j.jconrel.2004.07.032
Tabatt K, Kneuer C, Sameti M, Olbrich C, Müller RH, Lehr CM, Bakowsky U. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J Control Release. 200418; 97(2):321-32. https://doi.org/10.1016/j.jconrel.2004.02.029
Reithmeier H, Herrmann J, Göpferich A. Lipid microparticles as a parenteral controlled release device for peptides. J Control Release. 2001; 73(2-3):339-50. https://doi.org/10.1016/S0168-3659(01)00354-6
Jie, L; Tao, G; Changguang, W; Zhirong, Z; Zhirong, Z. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm. 2007; 340:153-162. https://doi.org/10.1016/j.ijpharm.2007.03.009
Olbrich C, Gessner A, Schröder W, Kayser O, Müller RH. Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption. J Control Release. 2004 18; 96(3):425-35. https://doi.org/10.1016/j.jconrel.2004.02.024
Morel S, Ugazio E, Cavalli R, Gasco MR. Thymopentin in solid lipid nanoparticles. Int J Pharm. 1996; 132:259-261. https://doi.org/10.1016/0378-5173(95)04388-8
Avner DL. Clinical experience with pantoprazole in gastroesophageal reflux disease, Clin Ther. 2000; 22(10):1169-1185. https://doi.org/10.1016/S0149-2918(00)83061-1
Cheer SM, Prakash A, Faulds D, Lamb HM Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acidrelated disorders, Drugs 2003; 63(1):101-133. https://doi.org/10.2165/00003495-200363010-00006
Poole P. Pantoprazole. Am J Health Syst Pharm. 2001; 58(11):999-1008. https://doi.org/10.1093/ajhp/58.11.999
Ramachandraiah M, Rami Reddy YV. Method development and validation of HPLC for the determination and quantification of pantoprazole, Bull Environ Pharmacol Life Sci. 2012; 1(8):39-42.
Thomas NR, Jack DR. Histamine and anti histaminic agents, in: Charles OW, Ole G, John HB, John MB (Eds.). Text Book of Organic Medicinal and Pharmaceutical Chemistry, eleventh ed., Lippincott Williams& Wilkins, Pennsylvania, 2004; pp. 696-730.
Beil W, Staar U, Sewing KF. Pantoprazole: a novel Hþ/K(þ)-ATPase inhibitor with an improved pH stability. Eur J Pharmacol. 1992; 218 (2-3):265-271. https://doi.org/10.1016/0014-2999(92)90178-7
Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders, Drugs 1996; 51(3):460-482. https://doi.org/10.2165/00003495-199651030-00012
Nishioka K, Nagao T, Urushidani T. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole. Biochem Pharmacol. 1999; 58(8):1349-1359. https://doi.org/10.1016/S0006-2952(99)00211-7
Schubert MA, Müller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles-Evaluation of the method and process parameters. Eur J Pharm Biopharm. 2003; 55:125-31. https://doi.org/10.1016/S0939-6411(02)00130-3
Parmar B, Mandal S, Petkar K, Sawant K. Valsartan loaded solid lipid naoparticles: development, characterization, in-vitro and exvivo evaluation. Int J Pharm Sci Nanotechnol. 2011; 4:1483-90. https://doi.org/10.37285/ijpsn.2011.4.3.7
Peltonen L, Koistinen P, Karjalainen M, Hakkinen A, Hirvonen J. The effect of cosolvents on the formulation of nanoparticles from low molecular weight poly(l)lactide, AAPS Pharm Sci Tech, 2002; 3:1-7. https://doi.org/10.1208/pt030432
Cui F, Oian F, Yin C. Preparation and characterization of mucoadhesive polymercoated nanoparticles. Int J Pharm. 2006; 316:154-161. https://doi.org/10.1016/j.ijpharm.2006.02.031
Kreuter J. Evaluation of nanoparticles as drug delivery systems. I: Preparation methods. J. Pharm. Acta Helv. 1983; 58(7):196-208.
Bourne DW. Pharmacokinetics In: Banker GS, Rhodes CT, eds. Modern Pharmaceutics. 4th ed, New York, NY: Marcel Dekker Inc, 2002:67-92.
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm.1983; 15:25-35. https://doi.org/10.1016/0378-5173(83)90064-9
Rinaki E, Valsami G, Macheras P. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res. 2003; 20(12):1917-25. https://doi.org/10.1023/B:PHAM.0000008037.57884.11
Published
Abstract Display: 742 
PDF Downloads: 615 PDF Downloads: 125 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.